Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow.

Huber, Bärbel; Keller, Claus; Jenkins, Martin; Raza, Abid; Aurivillius, Magnus

Huber, Bärbel; Keller, Claus; Jenkins, Martin; Raza, Abid; Aurivillius, Magnus.

Affiliation

Huber B; Clinical Unit, Inamed GmbH, Gauting, Germany.
Keller C; Lung and Bronchial Medicine, Praxis Dr. Claus Keller, Frankfurt, Germany.
Jenkins M; Late Respiratory and Immunology Biometrics, AstraZeneca, Cambridge, UK.
Raza A; Medsearch UK Limited, Slough, UK.
Aurivillius M; AstraZeneca Research and Development, Pepparedsleden 1, Gothenburg 43183, Sweden.

Ther Adv Respir Dis ; 16: 17534666221107312, 2022.

Article in En | MEDLINE | ID: mdl-35815354

Subject(s)

Glycopyrrolate; Pulmonary Disease, Chronic Obstructive; Administration, Inhalation; Aged; Bronchodilator Agents; Budesonide/adverse effects; Cross-Over Studies; Double-Blind Method; Drug Combinations; Formoterol Fumarate/adverse effects; Humans; Lung; Pulmonary Disease, Chronic Obstructive/diagnosis; Pulmonary Disease, Chronic Obstructive/drug therapy; Treatment Outcome

Key words

budesonide; chronic obstructive pulmonary disease; dry powder inhaler; formoterol fumarate dihydrate; inhaled dual therapy; metered dose inhaler; peak inspiratory flow

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / Glycopyrrolate Type of study: Clinical_trials / Diagnostic_studies Limits: Aged / Humans Language: En Journal: Ther Adv Respir Dis Journal subject: PNEUMOLOGIA / TERAPEUTICA Year: 2022 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google